Trial
NCT00537511
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Carcinoma, Small Cell
Intervention
Pomalidomide
Why stopped
This study was terminated for administrative reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-19